Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Post-Marketing Surveillance Study on the Status and Factors for the Development of Peripheral Neuropathy in Patients With HER2-Negative Inoperable or Recurrent Breast Cancer in Japan.

NCT02371174 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT02371174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02371174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Post-Marketing Surveillance Study on the Status and Factors for the Development of Peripheral Neuropathy in Patients With HER2-Negative Inoperable or Recurrent Breast Cancer in Japan.
Lead sponsor
Eisai Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
September 3, 2014
Completion date
January 21, 2018
Enrollment
651 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-negative breast cancer